Search

Your search keyword '"Goldgar, David E"' showing total 1,280 results

Search Constraints

Start Over You searched for: Author "Goldgar, David E" Remove constraint Author: "Goldgar, David E"
1,280 results on '"Goldgar, David E"'

Search Results

51. Supplementary Table 3 from Rare Mutations in RINT1 Predispose Carriers to Breast and Lynch Syndrome–Spectrum Cancers

52. Supplementary Figure 2 from Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer

53. Supplementary Table 1 from Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer

54. Data from Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer

55. Supplementary Figure 3 from Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer

56. Supplementary Figure 1 from Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer

57. Supplementary Figure 1 from Rare Mutations in RINT1 Predispose Carriers to Breast and Lynch Syndrome–Spectrum Cancers

58. Supplementary Table 2 from Rare Mutations in RINT1 Predispose Carriers to Breast and Lynch Syndrome–Spectrum Cancers

59. Supplementary Table 1 from Rare Mutations in RINT1 Predispose Carriers to Breast and Lynch Syndrome–Spectrum Cancers

60. Supplementary Methods from Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer

61. Data from Rare Mutations in RINT1 Predispose Carriers to Breast and Lynch Syndrome–Spectrum Cancers

62. Table S1 from A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk

63. Online Supplementary Materials from A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk

64. Supplementary Tables and References from BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer

65. Supplementary Methods and Tables from The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers

67. Supplementary Table 2 from Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

69. Supplementary Tables 1-4 from Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

70. Supplementary Table 3 from Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

71. Data from Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

72. Data from BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer

74. Supplementary Figures from BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer

75. Supplementary Figure 1 from A Classification Model for BRCA2 DNA Binding Domain Missense Variants Based on Homology-Directed Repair Activity

76. Data from A Classification Model for BRCA2 DNA Binding Domain Missense Variants Based on Homology-Directed Repair Activity

77. Supplementary Figure Legends 1-2 from A Classification Model for BRCA2 DNA Binding Domain Missense Variants Based on Homology-Directed Repair Activity

78. Supplementary Figure 2 from A Classification Model for BRCA2 DNA Binding Domain Missense Variants Based on Homology-Directed Repair Activity

79. Supplementary Table 2 from A Classification Model for BRCA2 DNA Binding Domain Missense Variants Based on Homology-Directed Repair Activity

80. Supplementary Table 1 from A Classification Model for BRCA2 DNA Binding Domain Missense Variants Based on Homology-Directed Repair Activity

81. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2

82. Abstract GS4-04: Population-based Estimates of contralateral Breast Cancer Risk among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2

83. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2.

84. A Likelihood Ratio Approach for Utilizing Case-Control Data in the Clinical Classification of Rare Sequence Variants : Application to BRCA1 and BRCA2

85. A likelihood ratio approach for utilizing case-control data in the clinical classification of rare sequence variants:Application to BRCA1 and BRCA2

86. Publisher Correction: Shared heritability and functional enrichment across six solid cancers

87. Shared heritability and functional enrichment across six solid cancers

89. Abstract A003: Risks of ductal carcinoma in situ of the breast associated with pathogenic variants in cancer predisposition genes

90. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2

91. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

92. Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants

94. The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium

95. Pancreatic cancer as a sentinel for hereditary cancer predisposition

96. Association analysis identifies 65 new breast cancer risk loci

97. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers

98. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

99. Clinical, splicing, and functional analysis to classify BRCA2 exon 3 variants:Application of a points-based ACMG/AMP approach

100. Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants

Catalog

Books, media, physical & digital resources